• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    UroGen Pharma Ltd. - Ordinary Shares (NQ:URGN)

    37.65 -0.37 (-0.97%)
    Streaming Delayed Price Updated: 3:46 PM EDT, Jul 6, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about UroGen Pharma Ltd. - Ordinary Shares

    < Previous 1 2 3 4 5 6 7 8 9 Next >
    News headline image
    UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From UroGen Pharma Ltd.
    Via GlobeNewswire
    News headline image
    UroGen Announces Agreement Resolving Patent Litigation Relating to JELMYTO® (mitomycin) for pyelocalyceal solution
    From UroGen Pharma Ltd.
    Via GlobeNewswire
    News headline image
    UroGen Pharma to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
    From UroGen Pharma Ltd.
    Via GlobeNewswire
    News headline image
    UroGen Reports 94.5% Six-Month Duration of Response in Phase 3 UTOPIA Trial, Advancing UGN-103 Toward Potential Approval in Recurrent Low-Grade Intermediate-Risk NMIBC
    From UroGen Pharma Ltd.
    Via GlobeNewswire
    News headline image
    ZUSDURI Median Duration of Response Still Not Reached with 64.5% 36-month Duration of Response in the Pivotal ENVISION Trial
    From UroGen Pharma Ltd.
    Via GlobeNewswire
    News headline image
    UroGen Pharma to Present at Upcoming Investor Conferences
    From UroGen Pharma Ltd.
    Via GlobeNewswire
    News headline image
    UroGen Reports ZUSDURI™ Revenue More Than Doubled Quarter-over-Quarter and Provides First Quarter 2026 Financial Results and Highlights
    From UroGen Pharma Ltd.
    Via GlobeNewswire
    News headline image
    UroGen Pharma to Report First Quarter 2026 Financial Results on Wednesday, May 6th, 2026
    Conference Call and Webcast Scheduled for Wednesday, May 6th, 2026, at 10:00 AM ET 
    From UroGen Pharma Ltd.
    Via GlobeNewswire
    News headline image
    Journal of Urology Publishes ENVISION Trial Results Showing 72.2% 24-Month Duration of Response with ZUSDURI
    From UroGen Pharma Ltd.
    Via GlobeNewswire
    News headline image
    UroGen Applauds BCAN’s New Faces of Bladder Cancer Report Highlighting Recurrence Burden and Fear of Recurrence
    From UroGen Pharma Ltd.
    Via GlobeNewswire
    News headline image
    UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From UroGen Pharma Ltd.
    Via GlobeNewswire
    News headline image
    UroGen Announces ZUSDURI™ Launch is On-Track and Reports Fourth Quarter and Full Year 2025 Financial Results
    From UroGen Pharma Ltd.
    Via GlobeNewswire
    News headline image
    UroGen Announces Refinanced Term Loan Agreement with Pharmakon Advisors
    From UroGen Pharma Ltd.
    Via GlobeNewswire
    News headline image
    ZUSDURI™ Achieves Durable Complete Responses Across EORTC Risk Groups in Patients with Recurrent LG-IR-NMIBC
    From UroGen Pharma Ltd.
    Via GlobeNewswire
    News headline image
    UroGen Pharma to Present at the TD Cowen 46th Annual Health Care Conference
    From UroGen Pharma Ltd.
    Via GlobeNewswire
    News headline image
    UroGen Pharma to Report Fourth Quarter and Full-Year 2025 Financial Results on Monday, March 2, 2026
    Conference Call and Webcast Scheduled for Monday, March 2, 2026 at 10:00 AM ET 
    From UroGen Pharma Ltd.
    Via GlobeNewswire
    News headline image
    UroGen Pharma to Present at the Guggenheim Securities Emerging Outlook: Biotech Summit
    From UroGen Pharma Ltd.
    Via GlobeNewswire
    News headline image
    Permanent J Code for ZUSDURI™ Now in Effect, Expanding Patient Access to Innovative Bladder Cancer Therapy
    From UroGen Pharma Ltd.
    Via GlobeNewswire
    News headline image
    UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From UroGen Pharma Ltd.
    Via GlobeNewswire
    News headline image
    UroGen Pharma to Present at the Piper Sandler 37th Annual Healthcare Conference
    From UroGen Pharma Ltd.
    Via GlobeNewswire
    News headline image
    UroGen Reports Third Quarter 2025 Financial Results as ZUSDURI™ Launch Gains Momentum
    From UroGen Pharma Ltd.
    Via GlobeNewswire
    News headline image
    UroGen Reports 77.8% Three-Month Complete Response Rate from Phase 3 UTOPIA Trial of UGN-103 and Receives FDA Agreement on NDA Submission Strategy in Recurrent LG-IR-NMIBC Based on UTOPIA Trial
    From UroGen Pharma Ltd.
    Via GlobeNewswire
    News headline image
    UroGen Pharma to Present at Guggenheim Securities Healthcare Innovation Conference
    From UroGen Pharma Ltd.
    Via GlobeNewswire
    News headline image
    UroGen Pharma to Report Third Quarter 2025 Financial Results on Thursday, November 6th, 2025
    Conference Call and Webcast Scheduled for Thursday, November 6th, 2025, at 10:00 AM ET 
    From UroGen Pharma Ltd.
    Via GlobeNewswire
    News headline image
    Centers for Medicare and Medicaid Services Assigns Permanent J Code for ZUSDURI™ Effective January 1, 2026
    From UroGen Pharma Ltd.
    Via GlobeNewswire
    News headline image
    ZUSDURI™ Clinical Review Published in Reviews in Urology™ Highlights Durable Efficacy and Manageable Safety Profile in Recurrent Low-Grade, Intermediate-Risk Non–Muscle Invasive Bladder Cancer
    From UroGen Pharma Ltd.
    Via GlobeNewswire
    News headline image
    UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From UroGen Pharma Ltd.
    Via GlobeNewswire
    News headline image
    UroGen Pharma to Present at Upcoming Investor Conferences
    From UroGen Pharma Ltd.
    Via GlobeNewswire
    News headline image
    UroGen Pharma Expands Commercial Portfolio with Launch of ZUSDURI™ and Reports Second Quarter 2025 Financial Results
    From UroGen Pharma Ltd.
    Via GlobeNewswire
    News headline image
    UroGen Announces 24-Month Duration of Response of 72.2% from the Pivotal Phase 3 ENVISION Trial of ZUSDURI, the First and Only FDA-Approved Medicine for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer
    From UroGen Pharma Ltd.
    Via GlobeNewswire
    < Previous 1 2 3 4 5 6 7 8 9 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.